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MicroRNAs (miRNAs) are small non-coding RNA which have been shown to regulate
gene expression. The alteration ofmiRNAs expression has been associated with several
pathological processes, including neurodegeneration. In the search for easily accessible
and non-invasive biomarkers for Alzheimer’s disease (AD) diagnosis and prognosis,
circulating miRNAs are among the most promising candidates. Some of them have been
consistently identified as AD-specific miRNAs and their targets also seem implicated
in pathophysiological processes underlying AD. Here, we review the emerging role for
miRNA in AD, giving an overview on general miRNAs biology, their implications in AD
pathophysiology and their potential role as future biomarkers.
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Alzheimer’s disease (AD) is a progressive neurodegenerative dis-
order and the most common form of dementia in the world. AD
affects more than 20% of individuals over 80 years of age, and epi-
demiological data predict that by 2050 over 35 millions of people
will be affected, with a significant social and economic burden
(Danborg et al., 2014). Clinically, AD is typically characterized
by progressive memory loss, impairment of other cognitive func-
tions and inability to perform activities of daily living. The earliest
clinical stage of AD is defined as mild cognitive impairment
(MCI), and it is characterized by impairment in memory and/or
others cognitive domains but preserved functional abilities, with
an annual conversion rate from MCI to AD of 15%. To date, the
available therapeutic agents are only able to slow disease progres-
sion, with limited benefits (Kim et al., 2014). Thus, there is an
urgent need to identify new potential biomarkers which could
help in early diagnosis at the prodromal stages.
Pathologically, AD brain is characterized by two major protein
abnormalities: extracellular amyloid-β (Aβ) deposition and intra-
cellular neurofibrillary tangles (NFT) formation, both ultimately
leading to extensive neuronal degeneration. Aβ peptides derive
from sequential cleavage of membrane-spanning amyloid precur-
sor protein (APP) by beta-site APP cleaving enzyme 1 (BACE1)
and the γ-secretase complex containing the presenilin (PSEN)
proteins in the catalytic domain. The NFT pathogenesis is less
understood, however it is known that NFT derive from abnor-
mal aggregation of hyperphosphorylated microtubule associated
tau protein. However, several other pathological mechanisms are
being investigated as potential contributors to AD pathology
(Bonda et al., 2011; Demetrius and Driver, 2013; Femminella
et al., 2013, 2014; Dineley et al., 2014). Less that 5% cases of
AD are familial, with autosomical dominant mutations in APP,
PSEN1, or PSEN2 genes; the vast majority of AD cases are spo-
radic and multifactorial, andseveral genetic polymorphisms have
been proposed as increased risk factors for the disease. Among
these, the ε4 allele of the Apolipoprotein E (APOE) is the best
characterized predisposing factor for sporadic AD (Hyman et al.,
2012).
In the search for reliable biomarkers in AD, great atten-
tion has focused on Aβ and tau measurement in cerebrospinal
fluid (CSF) and blood, together with neuroimaging techniques
looking at glucose metabolism (FDG-PET), amyloid deposition
(Pittsburgh compound B-PET and derivatives) and hippocam-
pal volume measurement on MRI (Jack and Holtzman, 2013;
Femminella and Edison, 2014). However, none of these tools
alone can help in diagnosis and a multi-marker approach is
currently recommended. Thus, the availability of easily accessi-
ble and non-invasive biomarkers is of significant value: in this
vein, microRNA (miRNA) research could represent an interesting
potential.
BASICS OF miRNAs
miRNAs are a novel class of small (18–25 nucleotides), single-
stranded non-coding RNAs involved in the post-transcriptional
regulation of gene expression. Their mechanism of action is medi-
ated by complementar binding to the 3′ untranslated region
(3′UTR) ofmRNA, leading to degradation or translational repres-
sion of the target mRNA (Goodall et al., 2013). In the cellular
nucleus, a primary transcript (pri-miRNA) is generated by RNA
polymerase II; subsequently, the RNAseDrosha digests the pri-
miRNA to release hairpin structures called pre-miRNA which are
transported to the cytoplasm. Here, another RNAse called Dicer
cleaves the pre-miRNA to generate double-stranded miRNA,
which then binds to Argonaute (Ago) proteins. Then, only one
strand is retained and associates to the RNA-induced silencing
complexes (RISC) to control mRNA translation (Goodall et al.,
2013).
miRNAs are involved in almost all biological processes, such
as proliferation, development, apoptosis, inflammation and their
expression is highly regulated, either by enzymes which stabi-
lize mature miRNAs or by epigenetic mechanisms such as DNA
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methylation or histone modification. miRNAs undergo a specific
tissutal and temporal distribution, as indicated by several studies
on miRNA profiling in different chronic diseases and they have
been found in all human biofluids. In particular, these small RNAs
have demonstrated being stable in cerebrospinal fluid (CSF) and
blood, probably thanks to the fact that they can be transported by
liposomes or lipoproteins which prevent them from degradation
(Dorval et al., 2013).
Different methods can be used to measure miRNAs levels in
biofluids. Among them, themost commonly used aremicroarrays
and quantitative PCR. While microarrays analysis is a high-
throughput technique used for a non-targeted approach when
several miRNAs need to be analyzed, PCR is more sensitive
and usually indicated for the validation of results obtained from
microarray analysis (Maciotta et al., 2013).
miRNAs IN AD
It has been demonstrated that specific miRNAs are expressed
in the central nervous system (CNS), where they regulate neu-
ronal differentiation, synaptic plasticity and neurite outgrowth.
In 2007, Landgraf et al. also showed that cluster analysis based
on the expression of orthologous miRNAsseparates the human
adult brain regions from those of adult rat brain, with the excep-
tion of the hippocampus region; moreover, adult and embryonic
brain tissues cluster separately (Landgraf et al., 2007). Several
studies using profiling tecniques have shown that there is miR-
NAs dysregulation in AD human brain, despite some differences
probably related to non-homogeneous esperimental conditions.
Wang et al have specifically assessed miRNA expression in human
cerebral cortical gray matter (GM) and white matter (WM) in
order to provide some insights into the difference between GM
and WM miRNAin AD pathology. They found that some well-
characterized miRNAs were substantially enriched in WM but
most of the miRNA expression variability that correlated with the
presence of early AD-related pathology was seen in GM, confirm-
ing that downregulation of a set of miRNAs in GM (including sev-
eral miR-15/107 genes and miR-29 paralogs) correlated strongly
with the density of diffuse amyloid plaques detected in adjacent
tissue. Moreover, particular subsets of miRNAswere coordinately
expressed in relation to AD-related pathology, supporting the
hypothesis that patterns of miRNA expression in cortical GMmay
contribute to AD pathogenesis (Wang et al., 2011).
In the following section we will describe some of the miRNAs
that are possibly related to AD pathology and have been consis-
tently identified as dysregulated in AD (Table 1) (Van den Hove
et al., 2014).
miR-9: miR-9 is encoded by three different genes and is one
of the most frequently altered miRNAs found in AD. It is highly
expressed in fetal hippocampus while it is downregulated in AD
brains; addition of Aβ peptides to primary neuronal cell cultures
has been shown to downregulate this small RNA (Krichevsky
et al., 2003). The targets of miR-9 include the fibroblast growth
factor receptor 1 (FGFR1), NFkB and sirtuin 1 (SIRT1), a deacety-
lase interacting with tau and probably contributing to the forma-
tion of hyperphosphorylated forms. Moreover, miR-9 also targets
the transcription factor REST, which is implicated in silenc-
ing neuronal gene expression in non-neuronal cells (Van den
Hove et al., 2014). In particular, it has been demonstrated that
REST contains miRNA recognition elements for miR-9 and, vice
versa, miR-9 is processed from a primary transcript which has
sequences that can be occupied by REST. Further evidence on
the important function of miR-9 derives from studies in patients
affected with Hutchinson-Gilford progeria syndrome (HGPS),
who exhibit systemic premature aging without any relevant cog-
nitive impairment. It has been shown indeed that in neuronal cells
of HGPS patients, the toxic accumulation of progerin protein is
prevented by the expression of miR-9 in these cells.
miR-107: this small RNA has been reported to be down-
regulated in temporal cortex at an early stage of AD (Nelson
and Wang, 2010). Its expression has a negative correlation with
BACE1 and with neuritic plaque density, as well as neurofibrillary
tangles and it has been proven that it targets BACE1, thus regulat-
ing amyloid production. Moreover, it has been demonstrated that
miR-107 can also modulate cyclin-dependent kinase 5 (CDK5),
which is known to be dysregulated in AD, and the metallopro-
teinase ADAM10, involved in APP processing (Goodall et al.,
2013).
miR-29: this is a family of miRNAs whose expression is
inversely correlated with BACE1 and in neuronal cellular mod-
els it has been shown to increase amyloid production in vitro
(Hebert et al., 2008). Other studies have suggested that miR-29
family might play a role in brain aging, as well as in microglial
activity modulation. Among the targets of miR-29 family are the
microglial modulators Insulin-like growth factor-1 (IGF-1) and
fractalkine ligand (CX3CL1). Indeed, higher expression of miR-
29 in the brain of aged mice was associated with reduced mRNA
levels of IGF-1 and CX3CL1. Moreover, increased expression of
miR-29b in human cortical tissue was negatively correlated with
IGF-1 and CX3CL1 expression.
miR-34: this is also a family of miRNAs which has been
implicated in several physiological processes. In AD, it seems
that miR-34 regulate the expression of p53, that is associated to
tau phosphorylation (Hooper et al., 2007). Moreover, miR-34 is
found at high levels in the hippocampus of patients with AD and
in transgenic mouse models of the disease. In these, the down-
regulation of miR-34 is able to rescue some cognitive abilities
(Zovoilis et al., 2011).
miR-181: this miRNA has been involved in different disease
pathophysiological processes as a regulator of genes such as onco-
gene RAS and tumor necrosis factor alpha. In AD, miR-181
is correlated with Aβ levels in human AD brain and in vitro
experiments have shown that Aβ is able to downregulate miR-
181 expression in primary humanastrocyes cultures. Moreover,
miR-181 has been suggested as one of the regulators of SIRT1
expression (Schonrock et al., 2012a,b).
miR-106: Both miR-106a and miR-106b have been shown to
directly bind to APP mRNA and are downregulated in the tem-
poral cortex of AD patients. Notably, they can also regulate the
expression of the transporter ABCA1, which is involved in ApoE
production, suggesting that these miRNAs might have multiple
roles in AD pathophysiological processes (Kim et al., 2012).
miR-146a: miR-146a is a known regulator of inflammation-
related mRNA, such as the complement factor H which is down-
regulated in AD brains and acts as an inflammatory response
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Table 1 | Some of the miRNAs most commonly associated with AD.
MiRNA Role in AD pathophysiology Evidence in AD patients References
MiR-9 Addition of Aβ peptides to primary neuronal cell
cultures has been shown to downregulate this small
RNA. Targets include FGFR1, NFkB and SIRT1
Down regulated in patient serum Krichevsky et al., 2003
MiR-107 Negative correlation with BACE1 and neuritic plaque
density; targets BACE1, CDK5 and the
metalloproteinase ADAM10
Downregulated in temporal cortex of AD patients Nelson and Wang, 2010;
Goodall et al., 2013
MiR-29 Inversely correlated with BACE1; in neuronal cellular
models it has been shown to increase amyloid
production in vitro
Downregulation in human AD temporal cortex,
cerebellum and patient serum
Hebert et al., 2008
MiR-34 Regulates the expression of p53, that is associated to
tau phosphorylation
High expression levels in the hippocampus of
patients with AD
Hooper et al., 2007;
Zovoilis et al., 2011
MiR-181 Aβ is able to downregulate MiR-181 expression in
primary human astrocyes cultures; regulates SIRT1
expression
Downregulated in human temporal cortex and
patient serum
Schonrock et al., 2012a,b
MiR-106 Directly bind to APP mRNA; can also regulate the
expression of the transporter ABCA1, which is involved
in ApoE production
Downregulated in the temporal cortex of AD
patients
Kim et al., 2012
MiR-146a Regulator of inflammation-related mRNA, acts as an
inflammatory response repressor in the CNS
“Selective” upregulation in brain regions affected
by AD pathology, such as temporal cortex and
hippocampus
Sethi and Lukiw, 2009
MiR-155 Appears to have specific effects on complement factor
H (CFH) down-regulation in neurodegenerative brain
Upregulated in Down’s syndrome, a congenital
human neurological disorder that shows a
remarkable AD-like neuropathology with age
Lukiw and Alexandrov,
2012
repressor in the CNS. MiR-146a has also shown a “selective”
upregulation in brain regions affected by AD pathology, such as
temporal cortex and hippocampus, while normal levels have been
found in non-affected regions (Sethi and Lukiw, 2009).
Not only those described above, but also other miRNAs have
been associated with AD, such as miR-124, miR-132, and miR-
153, and other neurodegenerative diseases. Most of them have
shown implications in APP processing, neuroinflammation, tau
phopshorilation and ApoElipidization and some of them seem to
be involved in more than one of these processes, suggesting that
they can also mediate cross-talk among the different pathologi-
cal processes underlying AD (Goodall et al., 2013; Van den Hove
et al., 2014).
miRNAs AS BIOMARKERS IN AD
To date, the diagnosis of probable AD is based on clinical and
neuropsychological evaluation, structural (MRI) and functional
(PET) neuroimaging techniques, and CSF determination of lev-
els of Aβ and tau. However, this combined biomarkers approach
results in a sensitivity of about 93% and specificity of 55%. Thus,
several studies have tried to establish the potential role of other
biomarkers and miRNAs have been extensively investigated at
this aim, to be used for screening, differential diagnosis and dis-
ease progression monitoring (Jack and Holtzman, 2013). A recent
systematic review has shown that 10 miRNAs display a signif-
icantly different expression in AD compared to controls in at
least two studies and more than thirty miRNAs are able to dis-
tinguish between two neurodegenerative diseases (Danborg et al.,
2014).The potential of miRNAs as biomarkers derives also from
their unique secretory properties, as they can exert their biological
effects both close by or at a distance, can regulate multiple target
genes simultaneously and can affect several cell types, being deliv-
ered independently of cell-to-cell contact (Schwarzenbach et al.,
2014). Indeed, extracellular miRNAs seem to derive mainly from
three sources: (1) passive leakage from injured cells; (2) active
secretion via microvescicles, released by almost all cell types; (3)
active secretion in complexes of miRNA-associated proteins, such
as Argonaute2. However, the details of these mechanisms still
need further elucidation (Chen et al., 2012).
Following we would like to summarize the findings of the
most significant studies that have investigated the potential role
of miRNAs as biomarkers in AD (Table 1).
Schipper et al. (2007) searched for possible differences in the
levels of 462 human miRNAs (from let-7 family to miR-663)
isolated from blood mononuclear cells (BMC) obtained from
sporadic AD patients and age-matched controls. The Authors
found that plasma levels of miR-34a and 181b were upregu-
lated in AD subjects, with miR-181b showing a higher increase
in ApoE4-positive AD subjects. Interestingly, among the puta-
tive targets of the miR-34a and 181b were mRNAs encoding for
Transcription/Translation and Synaptic Activity proteins; more-
over, such transcripts were also targeted by miRNAs involved
in the regulation of Injury response and Redox homeostasis
(Schipper et al., 2007). Subsequently, Cogswell et al. performed
by miRNAs profiling the expression of over 300 miRNAsin
hippocampus, medial frontal gyrus, andcerebellum from early
and late stage AD compared to age-matched controls, reveal-
ing that expressionchanges in key miRNAsare consistent with the
regional and time-dependent features of AD pathologyand are
linked through their targets to known and novel pathways of
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disease. These authors additionally discovered that miRNAscould
be detected in CSF and that CSF miRNAs are indeed altered in
AD, in particular miRNAs related tomultiple disease related path-
ways such as immune cell differentiation and innate immunity
(Cogswell et al., 2008).
Several miRNAs, including the specific pro-inflammatory
miRNA-9, miRNA-125b, miRNA-146a, and miRNA-155, were
found to be increased in both extracellular fluid (ECF) and CSF
of AD patients. Such miRNAs derive from the cleavage of NF-κB-
regulated pre-miRNA precursor, and regulate innate immune and
inflammatory responses in AD brain. Interestingly, miRNA-9,
miRNA-125b, miRNA-146a, miRNA-155 are also released in vitro
by human primary neuronal-glial cells treated with ECF obtained
from AD subjects. This signaling network between CSF and ECF
suggest a possible role for CNS miRNAs as paracrine mediators
(Alexandrov et al., 2012).
Similar findings were reported by Lukiw et al., who show
that two proinflammatorymiRNAs, miRNA-146a, and miRNA-
155, are abundant in ECF and in CSF of AD patients and that
these miRNAs are secreted by human brain cells stressed with
factors known to be elevated in AD brain. Moreover, they demon-
strated that a conditioned medium containing miRNA-146a and
miRNA-155, induces inflammatory gene expression in control
brain cells, an effect that is mediated in part by the downregu-
lation of the important immune system regulator CFH (Lukiw
and Alexandrov, 2012). Interestingly, they further demonstrated
that these effects are suppressed using anti-miRNA-146aand anti-
miRNA-155, suggesting that anti-miRNA strategies may be useful
in the prevention of miRNA mediated disease spreading (Lukiw
et al., 2012).
Lehmann and colleagues characterized the role of the miRNA
let-7b as an activator of toll-like receptor 7 (TLR7) in both
immune cells and neurons. They found that CSF from individuals
with AD contains increased amounts of let-7b, and extracellular-
introduction of let-7b into the CSF of wild-type mice by intrathe-
cal injection resulted in neurodegeneration. They hypothesized
that miRNAs such as let-7bare released under pathological con-
ditions and stimulate TLR7, thereby sending a “danger” signal to
neurons; this may cause further spread of CNS damage in classical
neurodegenerative diseases, such as AD (Lehmann et al., 2012).
Importantly, the expression levels of putative miRNAsas diag-
nostic markers has also been evaluated in the blood sera of AD
patients, showing that miR-137, -181c, -9, -29a/b were downreg-
ulated in a subgroup of mild and severe sporadic AD as well as in
mouse risk factor models (Geekiyanage et al., 2012).
CONCLUSIONS
Circulating miRNAs are one of the most promising biomark-
ers for AD and for discrimination between neurodegenerative
diseases. Some of them have been consistently identified as
AD-specific miRNAs and their targets also seem implicated in
pathophysiological processes underlying AD. However, although
miRNAs are considered to be stable in biofluids, variability can
be due to sample handling and processing conditions, which may
induce even 1000-fold differences in specificmiRNAs levels. Thus,
standardization of procedures must be obtained, as well as stabil-
ity profiles for each biomarker. Moreover, there is evidence that a
single miRNA can regulate as many as 200 mRNAs and also one
mRNA can be regulated by multiple miRNAs. This concept could
be a potential limitation for a therapeutic development of miR-
NAs: the interference with several biological processes when using
miRNA agonist/antagonist delivery could be a limitation that is
difficult to overcome.
In conclusion, miRNAs have a great potential as biomarkers
in diagnosis, monitoring of disease progression and therapeutic
response in AD and in other neurodegenerative diseases. Further
studies are needed to better understand their role in physio-
logical and pathological conditions and to validate their use as
non-invasive biomarkers.
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